Richard Mailman, PhD
Richard Mailman, PhD, has had a decades-long interest in the design and discovery of novel dopamine receptor ligands. In 1994, his lab was also the first to discover, elaborate and name the major pharmacology research front now called functional selectivity, which is how drugs acting at a single receptor differentially activate or block selected signaling pathways of that receptor. His current research interest is focused on mechanisms of receptor signaling and how the resulting knowledge can be used for novel drugs with better therapeutic profiles. His research played a major role in the understanding of the mechanisms of action of aripiprazole and other third-generation antipsychotic drugs.
NOTE: If no session is listed above, this individual is a Chair or Co-chair of a session(s). Please see the individual session listings found in the Program for a full list of session participants.